Table 3.

Predictors of overall survival and progression-free survival in the subgroup of patients who received chemotherapy (n = 72)

VariableOverall survival
Progression-free survival
Univariate analysis
Multivariate analysis
Univariate analysis
Univariate analysis
Hazard ratio* (95% CI)PHazard ratio* (95% CI)PHazard ratio* (95% CI)PHazard ratio* (95% CI)P
Age (y)
    ≤482.189 (1.221-3.924)0.009NS1.868 (1.012-3.451)0.046NS
    >4811
Postoperative KPS
    ≥802.924 (1.641-5.209)0.0002.454 (1.346-4.473)0.0032.269 (1.224-4.205)0.009NS
    <80111
Oligodendroglial component
    Yes2.220 (0.986-4.996)0.0542.275 (0.957-5.433)0.0643.644 (1.294-10.258)0.0145.339 (1.806-15.779)0.002
    No1111
Ki-67
    ≤4.8%3.989 (2.127-7.481)0.0003.761 (1.889-7.487)0.0003.886 (2.022-7.471)0.0003.766 (1.942-7.302)0.000
    >4.8%1111
Ring enhancement
    No2.343 (1.296-4.233)0.0051.844 (0.981-3.466)0.0572.785 (1.496-5.186)0.001NS
    Yes111
Gross total resection
    Yes2.831 (1.483-5.404)0.0023.918 (1.947-7.881)0.0002.388 (1.232-4.627)0.0104.049 (1.999-8.201)0.000
    No1111
MGMT expression
    Negative1.057 (0.595-1.880)0.8492.121 (1.107-4.065)0.0231.050 (0.570-1.936)0.875NS
    Positive111
MGMT promoter status
    Methylated1.333 (0.565-3.143)0.512NS1.317 (0.535-3.243)0.550NS
    Unmethylated11
  • Abbreviations: CI, confidence interval; NS, not significant.

  • * Hazard Ratio of being alive.

  • Reference group.